Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Jun;24(3):301-16.
doi: 10.1023/b:cemn.0000022764.94760.3f.

Cell transplantation for Parkinson's disease: present status

Affiliations
Review

Cell transplantation for Parkinson's disease: present status

René Drucker-Colín et al. Cell Mol Neurobiol. 2004 Jun.

Abstract

1. Parkinson's disease (PD) is a neurodegenerative disorder caused by the loss of neurons in the substantia nigra pars compacta and a striatal deficiency of dopamine. PD typically affects people in late middle age and progresses slowly. In the early stages of the disease, treatment targeting the dopaminergic network is effective. However, with disease progression, transplantation is an option for repairing and replacing missing dopaminergic neurons. 2. In this review, we evaluate the tissue grafts and cellular therapies that have and are being considered. Clinical trials were originally derived from transplants of adrenal medullary chromaffin cells and embryonic nigral dopaminergic neurons in patients with PD. 3. Recently, novel molecular and cellular treatments are being utilized in animals and these include embryonic stem cells, fetal cells from pigs, or transfected cells. In spite of new molecular techniques and some 20 years of experience, the transplantation therapy for PD has today the same problems and results as the first reports which used neural fetal tissue or adrenal grafts.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. TINS12(10):366-374. - PubMed
    1. Allen, G. S., Burns R. S., and Tullipan, M. B. (1989). Adrenal medulary transplantation to the caudate nucleus in Parkinson's disease. Initial clinical results in 18 patients. Arch. Neurol.46:487-491. - PubMed
    1. Backlund, E.-O., Granberg, P.-O., Hamberger, B., Knutson, E., Martensson, A., Sedvall, G., Seiger, A., and Olson, L. (1985). Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg.62:169-173. - PubMed
    1. Barker, R. A. (2002). Repairing the brain in Parkinson's disease: Where next? Mov. Disord.17(2):233-241. - PubMed
    1. Björklund, L. M., Sánchez-Pernaute, R., Chung, S., Andersson, T., Ching-Chen, I. Y., McNaught, K. P., Brownell, A. L., Jenkins, B. G., Wahlestedt, C., Kim, K. S., and Isacson, O. (2002). Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. PNAS99(4):2344-2349. - PMC - PubMed

MeSH terms